Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth I Ataga

Showing results (11-20 of 133) with videos related to

Pageof 14
Sort By:
Hematology. American Society of Hematology. Education Program|December 9, 2023
Using disease-modifying therapies in sickle cell diseaseParul Rai, Kenneth I Ataga
The American Journal of Medicine|December 25, 2003
Hypercoagulability in sickle cell disease: a curious paradoxKenneth I Ataga, Eugene P Orringer
The American Journal of the Medical Sciences|January 7, 2010
Delayed hemolytic transfusion reaction in sickle cell diseaseLeslie P Scheunemann, Kenneth I Ataga
Hematology. American Society of Hematology. Education Program|February 20, 2015
Does hydroxyurea prevent pulmonary complications of sickle cell disease?Tyler W Buckner, Kenneth I Ataga
Current Molecular Medicine|November 11, 2008
Hypercoagulability in sickle cell disease and beta-thalassemiaSylvia T Singer, Kenneth I Ataga
American Journal of Hematology|September 16, 2015
Pulmonary endarterectomy as treatment for chronic thromboembolic pulmonary hypertension in sickle cell diseaseAshley T Freeman, Kenneth I Ataga
Hematology. American Society of Hematology. Education Program|November 21, 2007
Hypercoagulability in sickle cell disease: new approaches to an old problemKenneth I Ataga, Nigel S Key
Hematology. American Society of Hematology. Education Program|February 20, 2015
Pulmonary hypertension in sickle cell disease: diagnosis and managementKenneth I Ataga, Elizabeth S Klings
Expert Opinion on Pharmacotherapy|March 29, 2013
The acute chest syndrome of sickle cell diseasePayal C Desai, Kenneth I Ataga
Expert Opinion on Orphan Drugs|March 16, 2019
Advances in new drug therapies for the management of sickle cell diseaseKenneth I Ataga, Payal C Desai
Pageof 14

Showing results (11-20 of 133) with videos related to

Sort By:
Pageof 14
Hematology. American Society of Hematology. Education Program|December 9, 2023
Using disease-modifying therapies in sickle cell diseaseParul Rai, Kenneth I Ataga
The American Journal of Medicine|December 25, 2003
Hypercoagulability in sickle cell disease: a curious paradoxKenneth I Ataga, Eugene P Orringer
The American Journal of the Medical Sciences|January 7, 2010
Delayed hemolytic transfusion reaction in sickle cell diseaseLeslie P Scheunemann, Kenneth I Ataga
Hematology. American Society of Hematology. Education Program|February 20, 2015
Does hydroxyurea prevent pulmonary complications of sickle cell disease?Tyler W Buckner, Kenneth I Ataga
Current Molecular Medicine|November 11, 2008
Hypercoagulability in sickle cell disease and beta-thalassemiaSylvia T Singer, Kenneth I Ataga
American Journal of Hematology|September 16, 2015
Pulmonary endarterectomy as treatment for chronic thromboembolic pulmonary hypertension in sickle cell diseaseAshley T Freeman, Kenneth I Ataga
Hematology. American Society of Hematology. Education Program|November 21, 2007
Hypercoagulability in sickle cell disease: new approaches to an old problemKenneth I Ataga, Nigel S Key
Hematology. American Society of Hematology. Education Program|February 20, 2015
Pulmonary hypertension in sickle cell disease: diagnosis and managementKenneth I Ataga, Elizabeth S Klings
Expert Opinion on Pharmacotherapy|March 29, 2013
The acute chest syndrome of sickle cell diseasePayal C Desai, Kenneth I Ataga
Expert Opinion on Orphan Drugs|March 16, 2019
Advances in new drug therapies for the management of sickle cell diseaseKenneth I Ataga, Payal C Desai
Pageof 14